|
We are building a portfolio of compounds that have first-in-class and best-in-class potential through our own discovery research and clinical development initiatives.
more >
|
 |
03/09/10
Exelixis Announces Fourth Quarter and Full Year 2009 Financial Results
03/08/10
Exelixis Announces Restructuring
|
|
Abstracts Featuring Exelixis Compounds Accepted for Presentation at the 2009 AACR-NCI-EORTC International Conference.
more >
One abstract featuring Exelixis' XL184 was presented at the meeting from October 22-24, 2009.
more >
No events are scheduled at this time
|
|
Looking for a career at Exelixis? We are looking for people to join us as we turn our vision into reality.
more >
NASDAQ: EXEL
Mar 11 2010 10:04AM
PRICE: 6.27 +0.09
VOLUME: 133478 SHARES
20 minute delay
more >
|
